Oncovision took part at the Annual Congress of the European Association of Nuclear Mecine (EANM) last October. The event took place from October 28th to the 30th, and gathered the best specialists of the world in the nuclear medicine field.
We are pleased to invite you to see our pictures below.
Madrid, September 12, 2012. The private equity manager CRB Inverbío has made the first investment with its fund CRB Bio II, one of the largest funds in Spain specialized in the field of Life Sciences. The total investment of the funding round of the Spanish company Oncovision was 3 million euros, of which CRB Inverbío has invested €1.5 million to finance the company’s growth and global expansion. CRB Bio II Fund, which recently achieved a first closing of €30 million, intends to invest in 10-12 other innovative initiatives that contribute to the development of medicine and biomedical technology in a four-year horizon.
Bullnet Capital, a shareholder of Oncovision since 2006, also participated in the round as well as Axis, through its fund FOND-ICOpyme.
Oncovision (GEM Imaging SA) is a young and dynamic Spanish technology company which emerged in 2003 from the Corpuscular Physics Institute of Valencia (CSIC) and the University of Valencia. Recognized as "Best Innovative Technology Based Company in Spain 2012", and "Best Preclinical Launch in the United States 2011", among many other technology, innovation and export awards, Oncovision specializes in Molecular Vision applied to health sciences, with its main focus on diagnosis and treatment of multiple types of cancer and advanced research.
The company's goal is to create, develop and market original and innovative technology that will significantly improve the life expectancy and quality of life of people worldwide. Oncovision designs, manufactures and markets three revolutionary product lines aimed at cancer patients as well as patients suffering from neurological and heart disorders, and has become the new global standard in multimodal molecular vision technologies for diagnosis and treatment in Surgical Oncology, Diagnostics, Interventionist surgery and advanced research, with highly relevant clinical and advantages.
Oncovision technology is installed and is in active use in prestigious medical and research centers around the world, with strong evidence and support from global leaders in oncology and research as well as prestigious medical and scientific societies.
"The investment by CRB Inverbío, together with our current investors, is a very powerful boost to accelerate our growth in global markets with extraordinary potential, with original Spanish technology which is already having a direct positive impact on the lives of thousands of people. We are very satisfied with having reinforced our shareholder team with a new investor with long term vision and focus¨ said Gabriel Gonzalez Pavón, CEO of Oncovision.
Angel Santos, partner at CRB Inverbío states "Oncovision is the first investment of our new fund CRB Bio II, and we have selected this company for several reasons, including the strength of its technology, its active international presence in over 30 countries, its team with experience in nuclear physics, medicine, electronics and software, and especially for the confidence provided by its two partners: Axis and Bullnet Capital, who have been active for more than six years as a reference shareholder of the company "
About CRB Inverbío
Cross Road Biotech Inversiones Biotecnológicas is a private equity management firm specialized in the management of entities that invest in innovative, technology-based start-ups in the field of Life Sciences. The new firm benefits from the experience and know-how of Cross Road Biotech, which since 2005 has managed and invested in ten biotechnology companies that provide therapeutic and diagnostic solutions for illness of great relevance such as hypolactasia, Alzheimer's disease, chronic hepatitis and cancer. The closing of its second fund, CRB Bio II has recently been completed with a volume of 30 million Euros.
Company specialized in original technology medical imaging equipment. It was founded in 2003 as a spin-off of Corpuscular Physics Institute of the CSIC in Valencia. It is a world leader in the design and manufacture of equipment used for both radioguided personalized surgery, preclinical disease research and drug development and in the diagnosis and treatment of multiple cancers. It has successfully marketed three revolutionary product lines, which are used by the many of the most prestigious hospitals and research centers worldwide.
Axis, Participaciones Empresariales is a Venture Capital fund Management firm formed in June 1986. . It is 100% owned by ICO, the Spanish government investment agency. It manages the venture capital ICOpyme FOND FCR, endowed with resources amounting to 422 million euros, also owned 100% of the ICO. It currently has a portfolio of about 25 holdings in various sectors.
About Bullnet Capital
It is an Independent Spanish fund founded in 2001 by Javier Ulecia and Miguel del Cañizo, with the financial support of Bruno Entrecanales. It specializes in Spanish high-tech companies in the early stages and manages about 50 million euros. The company has made eleven investments to date. Among its investors is the European Investment Fund, Neotec Fondo de Fondos and ICOpyme FOND.
Oncovision participated, from 19th to 21st September, at the 32nd Congress organized by the European Society of Surgical Oncology.
Stand number 7 in the Congress Palace in Valencia.
Exhibition opening hours:
Wednesday 19 September 11:30-20:15
Thursday 20 September 10:30-18:00
Friday 21 September 10:30-16:00
Oncovision will participate with an stand Nr. 806/808 at the The American Society of Breast Surgeons Annual Meeting that will be held at the Hotel JW Marriott Desert Ridge Resort and Spa in Phoenix, Arizona. Visitors will be informed about the new technologies applied to the radiodiagnostic by images of our equipments, Sentinella & Mammi.
Oncovision has been selected by AIDO (Optical and Imaging Technical Institute) as one of 50 innvoative companies in Spain.
The Social Council of the Polytechnic University of Valencia will hold next Friday December 16th at 11:45 pm in the Blue Cube of the Polytechnic City of Innovation in Valencia the eleventh edition of its annual awards. Rafael Ferrando, Chairman of Social UPV; Juan Julia, president of the Polytechnic, and José Císcar, Minister for Education, Training and Employment of the Generalitat will attend the event.
Why ONCOVISION has been awarded?
The company has been awarded in the category of Cooperation in R & D for their great contribution to the development of relations between the University and Society. Thus, this company has a collaboration agreement with the UPV to provide technology support and other services, especially in the field of research and development. Among other benefits, General Medical Imaging Equipment for technological supports to the University for the use of the isotope laboratory and X-ray chamber radiation service, and provides data acquisition systems for detectors.
Oncovision will participate at the Spanish Society of Senology and Breast Pathology Congress, in San Sebastián, in booth number 5. It will be a talk about MAMMI, dedicated breast PET designed and comercialized by Oncovision, next Friday, October 21st at 15h.
Oncovision has attended EANM 2011 with a great number of visitors.
Oncovision will be participating from today, 14th april to tomorrow in the I Endocrine Surgery National Meeting, taking place in the Bellvitge Hospital in Barcelona, Spain.